

ORIGINAL ARTICLE

Younger age at onset of sporadic Parkinson's disease among subjects occupationally exposed to metals and pesticides

Marcia H. RATNER^{1,2}, David H. FARB², Josef OZER², Robert G. FELDMAN^{1,2}, Raymon DURSO¹

¹ Department of Neurology, Boston University School of Medicine, Boston, USA

² Department of Pharmacology and Experimental Therapeutics, Boston University School of Medicine, Boston, USA

ITX070314A02 • Received: 07 May 2014 • Revised: 13 September 2014 • Accepted: 14 September 2014

ABSTRACT

An earlier age at onset of Parkinson's disease (PD) has been reported to be associated with occupational exposures to manganese and hydrocarbon solvents suggesting that exposure to neurotoxic chemicals may hasten the progression of idiopathic PD. In this study the role of occupational exposure to metals and pesticides in the progression of idiopathic PD was assessed by looking at age at disease onset. The effects of heritable genetic risk factors, which may also influence age at onset, was minimized by including only sporadic cases of PD with no family history of the disease (n=58). Independent samples Student *t*-test revealed that subjects with occupational exposure to metals and/or pesticides (n=36) were significantly ($p=0.013$) younger than unexposed controls (n=22). These subjects were then divided into three groups [high (n=18), low (n=18), and unexposed (n=22)] to ascertain if duration of exposure further influenced age at onset of PD. One-way ANOVA revealed that subjects in the high exposure group were significantly ($p=0.0121$) younger (mean age: 50.33 years) than unexposed subjects (mean age: 60.45 years). Subjects were also stratified by exposure type (metals vs. pesticides). These results suggest that chronic exposure to metals and pesticides is associated with a younger age at onset of PD among patients with no family history of the disease and that duration of exposure is a factor in the magnitude of this effect.

KEY WORDS: occupational exposure; pesticides; metals; Parkinson's disease; onset; age

Introduction

Parkinson's disease (PD) is a progressive neurodegenerative movement disorder characterized clinically by tremor, bradykinesia, gait disturbances, cogwheel rigidity, postural instability, hypomimia, hypophonia, and micrographia. The clinical manifestations associated with PD result from the loss of pigmented dopaminergic neurons in the pars compacta of the substantia nigra (Klawans & Cohen, 1970). Although the etiology of PD has not been fully elucidated studies suggest that PD is a multi-factorial disorder, which involves genetic and environmental factors (Tanner & Goldman, 1996; Seidler *et al.*, 1996; Kamel

et al., 2014; Tanner *et al.*, 2014; Singh *et al.*, 2014). Although studies have revealed evidence for familial forms of PD a genetic factor has not been identified in the majority of cases. As a result, the possible role of environmental and occupational exposures to neurotoxicants in the development of idiopathic PD has received considerable attention from the medical and public health communities (Ballard *et al.*, 1985; Pezzoli *et al.*, 1995; Tanner & Goldman, 1996; Seidler *et al.*, 1996; Menegon *et al.*, 1998; Savolainen *et al.*, 1998; Smargiassi *et al.*, 1998; Saunders-Pullman *et al.*, 1999; Feldman & Ratner, 1999; Priyadarshi *et al.*, 2000; Petrovitch *et al.*, 2002; Dawson & Dawson, 2003).

Environmental factors that have been associated with an increased risk of developing PD include pesticide exposure, rural living, well water consumption, and diet (Rajput *et al.*, 1987; Barbeau, 1987; Calne *et al.*, 1987; Liou *et al.*, 1997; Smargiassi *et al.*, 1998; Kuopio *et al.*, 1999; Petrovitch *et al.*, 2002). Despite decades of research, exposure to a specific neurotoxic chemical has never been shown to increase the

Correspondence address:

Marcia H. Ratner, PhD.

Department of Pharmacology and Experimental Therapeutics,
Boston University School of Medicine,
72 East Concord Street, L-601, Boston MA 02118, USA
E-MAIL: marcia@bu.edu

incidence or prevalence of idiopathic PD. Research has however begun to accumulate, suggesting that exposure to neurotoxic chemicals can influence age at onset of PD. Racette *et al.* (2001) found a significantly younger age at onset of PD among manganese-exposed welders. The mean age at onset among these welders was 46 years while the unexposed controls had a mean age at onset of 63 years ($p < 0.0001$). A similar study by Pezzoli *et al.* (2000) which looked at hydrocarbon exposure also revealed a younger age at onset among exposed subjects with PD. The neurotoxic substances most frequently encountered by the exposed subjects were acetone, 2-di-methyl-ethyl-ketone, n-hexane and its isomers, cyclo-hexane and its isomers, heptane and its isomers, ethyl-acetate, isobutylacetate, butyl-acetate, dichloropropane, trichloroethylene, trichloroethane, tetrachloroethylene, freon, toluene, and 1-methoxy-2-propanol. The exposed group had a mean age at onset of 55.2 years (± 9.8 years) compared with 58.6 years (± 10 years) for unexposed controls. The severity of symptoms was correlated with the duration and the intensity of exposure to hydrocarbons. In addition, the exposed subjects were less responsive to treatment and required a higher mean dosage of levodopa than did the unexposed controls. These findings were interpreted to suggest that hydrocarbon exposure might be involved in the pathogenesis of PD, which does not appear to have a major genetic component. These observations are important because these data provide evidence for a scientifically plausible interaction between a genetic predisposition and environmental risk factors. However, although Pezzoli *et al.* (2000) and Racette *et al.* (2001) have both provided evidence that age at onset of PD is influenced by occupational exposure to chemicals neither of these studies took specific measures to minimize the opportunity for interactions between exposure and known heritable genetic

risk factors which may also influence age at onset and thus, it is difficult to interpret these findings in relation to sporadic PD. Although Racette *et al.* (2001) reported that family history of PD was similar among exposed subjects and unexposed controls, over 50% ($n=8$) of the 15 exposed subjects included in this study had a positive family history of PD making the influence of genetics on age at onset in this relatively small sample population particularly difficult to interpret. Pezzoli *et al.* (2000) also reported that family history of PD was similar (approximately 25%) among exposed subjects and controls but again the influence of genetics on these data is difficult to interpret since subjects with a positive family history for PD were not excluded from the study or by stratification during data analysis.

To minimize the influence of genetic factors on age at onset of PD while further elucidating on the role of chemical exposure history we elected to look at age at onset among subjects with no family history of the disease (sporadic PD). It is hoped that this approach will not only reveal effects of exposure that could be masked by dominant genotypes but may also provide valuable insight that will be useful in the development of novel therapeutics that may be more beneficial for treating sporadic PD.

Methods

Human subjects

Human subjects and controls ($n=58$) participating in this study were drawn from the clinical population of patients with PD seen at the Movement Disorder Center at the Boston University Medical Center, Boston, Massachusetts. All subjects signed a Human Subjects Committee consent form. All subjects included in this study reported having no family history of PD among their first-degree relatives. These subjects were initially deemed eligible for the GenePD study (Maher *et al.*, 2002) but were later excluded because of a negative family history of PD among their first-degree relatives. No effort was made to include or exclude subjects based on gender or race. The diagnosis of PD was confirmed by a clinical evaluation by a Board Certified Neurologist specializing in movement disorders. Every subject included in this study met the Ward and Gibb diagnostic criteria for selection of subjects for research in PD (Ward & Gibb, 1990; Taylor *et al.*, 1999; Maher *et al.*, 2002) (Table 1).

A trained research assistant interviewed each subject about their occupational exposure to chemicals and recorded the information obtained during the interview on a structured questionnaire form as previously described (Maher *et al.*, 2002). The subject was questioned by the research assistant about whether he or she had worked for more than six months (cumulative exposure) in various industries with a recognized risk for occupational exposure to metals or pesticides. If the subject affirmed having worked in a specific industry, then he or she was asked about his or her history of exposure to specific neurotoxic compounds commonly encountered by workers employed in these industrial settings (Tables 1 and 2).

Table 1. Occupations associated with exposures to metal and pesticides. Subjects were asked if they had ever worked in any of the following industries with recognized risk for occupational exposure to metals or pesticides.

| Metals | Pesticides |
|-------------------------------------|--------------------------------------|
| Chemical manufacturing | Farm ranch or orchard |
| Metal finishing industry | Landscaping |
| Lumber or wood manufacturing | Forestry, paper mill, or woodworking |
| Electroplating | Rodent control |
| Battery manufacturing | Weed control |
| Glass, stone, or clay manufacturing | Crop dusting |
| Paper or pulp manufacturing | Pesticide manufacturing |
| Foundry | Pesticide applicator |
| Autobody repair | |
| Smelter | |

Categorization of exposed cases and unexposed controls

Exposed subjects

Subjects with no family history of PD who reported to have experienced at least six months of occupational exposure to metals and/or pesticides were included as exposed subjects in this study (n=36). Subjects reported their occupational exposure histories to a trained interviewer who recorded specifics about the nature of the exposure circumstances in a narrative note and categorized the subject's exposure circumstances based on the following four objective grouping criteria obtained from the questionnaire form used for the GenePD study (Maher *et al.*, 2002).

1. Less than once a month for less than 10 years.
2. Less than once a month for 10 years or more.
3. Once a month or more for less than 10 years.
4. Once a month or more for 10 years or more.

A maximum number of possible exposure days were calculated for each exposure category using these definitions (Table 3).

To determine if exposure duration influenced age at onset of PD we constructed a two-tiered exposure duration index based on the exposure data obtained by the interviewer. For the purposes of this study a low-level exposure was defined as that which occurred less than once per month for at least six months but for less than 10 years (category 1 from questionnaire). For example, one of the subjects in this category reported "light exposure" to insecticides, herbicides, fungicides, and rodenticides while working with stored grain and agricultural products at age 10. This low level exposure category was deemed the most likely to select for those subject's who had worked briefly either as teenagers or during career changes in occupational settings where there was a risk for occasional exposure to metals and pesticide. Exposure categories 2 though 4 from the questionnaire were defined as high-level exposures. For example, one subject in this category reported working as an autobody repair mechanic for 3 years with exposures to lead more than once per month. This grouping pattern was deemed the best for identifying those subjects who had either worked in occupations where overt recognized exposures occurred relatively frequently (more than once per month) or had worked for more than 10 years in careers that involved the risk for recognized occasional exposures and the potential for unrecognized exposures. The interviewer's narrative notes were used to aid in categorizing the subject's exposure level and in determining the average duration of exposure for subjects in these two groups.

Unexposed controls

Subjects with no family history of PD and no history of occupational exposure to heavy metals and/or pesticides were assigned to the control group (n=22).

Data analysis

Data was analyzed using SPSS software installed on a Macintosh computer (Apple Computer, Cupertino, CA) at 95% confidence intervals ($p=0.05$). Independent samples Student *t*-test was used for analysis of the effects of gender

Table 2. Potential occupational chemical exposures in various industries. List of metals and pesticides exposures inquired about and recorded on questionnaire by interviewer. Specific examples of common insecticides, herbicides, fungicides, and rodenticides are provided.

| Metals | Pesticides |
|--------------|-----------------------|
| Mercury | Insecticides |
| Copper | Organochlorines (DDT) |
| Zinc | Carbamates (Sevin) |
| Manganese | OPCs (chlorpyrifos) |
| Iron | Pyrethroids |
| Magnesium | Herbicides |
| Lead | Paraquat |
| Other metals | Fungicides |
| | Maneb |
| | Rodenticides |
| | Diphacinone |

Table 3. Mathematical calculations showing differences in maximum possible days of occupational exposure for subjects in each category.

| Exposure category | Maximum possible exposure * |
|-------------------|--|
| Category 1 | 11 days × 9 years = max. exposure = 99 days |
| Category 2 | 11 days × 10 years = max. exposure >110 days |
| Category 3 | 13 days × 9 years = max. exposure >117 days |
| Category 4 | 13 days × 10 years = max. exposure >130 days |

* Assumes that subjects exposed less than once per month were not exposed more than 11 times per year and that subjects exposed more than once per month were exposed at least 13 times per year by definition. Likewise, assumes that subjects exposed for less than 10 years were not exposed for more than 9 years and subjects exposed for 10 years or more exposed for a minimum of 10 years by definition.

and smoking history on age at onset of PD. One-way analysis of variance (ANOVA) was used to ascertain if duration of exposure significantly influenced mean age at onset among the three groups of PD subjects stratified by levels of exposure to neurotoxic chemicals. ANOVA was also used to determine if age at onset of PD among subjects and controls was influenced by exposure to metals or pesticides. Post Hoc analysis of ANOVA data were performed using Tukey's HSD and the Least Significant Difference (LSD) tests. The Pearson correlation coefficient was used to determine if age at onset of PD was correlated with duration of occupational exposure.

Results

The mean age at onset of PD among the entire sample population (n=58) studied was 55.4 (range 34 to 80 years;

SD±10.95). Analysis of skewness and kurtosis indicated that the sample population had a normal distribution (data not shown).



The *a priori* hypothesis for this study was that occupational exposure to neurotoxic chemicals such as heavy metals and pesticides influenced age at onset of PD among subjects with no family history of the disease. To ascertain if occupational exposure history influenced age at onset of PD we compared exposed subjects with unexposed controls. The exposed subjects (n=36) were younger with a mean age at onset of PD of 53.09 years (SD±10.29). The unexposed controls (n=22) had a mean age at onset of PD of 60.45 years (SD±10.71). Importantly, independent samples *t*-test revealed that the difference in age at onset of PD in these two groups was significantly different ($t=2.5634$; $df=56$; $p=0.013$) (Figure 1).



To determine if age at onset of PD was further influenced by duration of exposure we stratified our subjects into three groups based on self-reported occupational exposure history. A two-tiered exposure duration index was used to stratify exposed subjects into high and low exposure groups. A low-level exposure was defined as that which occurred less than once per month for at least six months but for less than ten years. A high-level exposure was defined as that which occurred either: A) less than once per month for ten years or more; B) more than once per month for at least six months but for less than ten years; or C) more than once per month for ten years or more. The mean age at onset among subjects in the high-level exposure group which consisted of those subjects who were more likely to have held full-time professional positions working with metals or pesticides for several years or more was 50.33 years (SD±8.75). The mean age at onset among subjects in the low exposure group, which consisted primarily of subjects who briefly worked with metals or pesticides while young adults, was 56 years

(SD±11.15). The mean age at onset among unexposed controls was 60.45 years (SD±10.71). The range for ages at onset among the subjects in the high-level exposure group was 34 to 66 years with a median of 50.33 years. This is in contrast to the range of 45 to 80 years with mean age at onset of 60.45 years among the unexposed controls. ANOVA of the age at onset of PD data from subjects stratified into three groups (high, low and unexposed) at 95% confidence intervals using Tukey's HSD for post hoc comparisons revealed a significantly ($F=4.7913$; $p=0.0121$) younger age at onset of PD among subjects from the high exposure group suggesting that duration and frequency of exposure influences age at onset of PD (Figure 2). Independent samples *t*-test indicated that age at onset of PD among subjects in the low exposure group did not significantly differ ($p=0.207$) from that of the unexposed subjects in this study.

There was a significant ($r=-0.384$; $p=0.008$) negative correlation between age at onset of PD and duration of occupational exposure (Figure 3). By squaring of the absolute value of the correlation coefficient we derived the coefficient of determination ($R^2=0.147$) for these data which indicates that only about 15% of the variance in age at onset of PD seen in this sample population can be explained by duration of exposure. This finding indicates that other factors such as magnitude or intensity of exposure to metals and pesticides may have also influenced the younger age at onset seen in this population.


To better understand the influence of pesticide and metal exposures on age at onset of PD we stratified subjects by their pesticide and metal exposure histories. Although few subjects reported exposure to only one chemical, were able to stratify subjects by their primary exposure. Forty-seven percent (17/36) of the occupationally exposed subjects participating in this study reported occupational exposure to pesticides the remaining were





exposed to metals. ANOVA using the Least Significant Difference (LSD) test for post hoc analysis revealed that subjects who reported occupational exposure to metals had a significantly ($p=0.045$) younger age at onset of PD (mean age at onset 52.84 years; $SD\pm 9.66$ years) than the unexposed controls (mean age at onset 60.45 years; $SD\pm 10.71$ years) (Figure 4). Subjects exposed to primarily to pesticides were younger than unexposed controls with a mean age at onset of 53.53 years ($SD 11.23$ years) but his difference was not statistically significant ($p=0.057$). The mean age at onset of PD among subjects exposed to metals and pesticides was very similar and did not approach statistical significance (Figure 5).

To determine if smoking history, which has previously been associated with a decrease in the incidence of PD (Smargiassi *et al.*, 1998; Taylor *et al.*, 1999), had any influence on age at onset of sporadic PD among the subjects participating in this study we stratified subjects by smoking history. None of the subjects in this study currently smoked. Smoking history was similar for unexposed (40%) and exposed subjects (47%). The mean age at onset of PD among former unexposed smokers ($n=26$) was 59.08 ($SD\pm 11.31$). The mean age at onset of PD among former exposed smokers ($n=32$) was 53.38 ($SD\pm 10.12$). Independent samples *t*-test revealed that this difference was significant ($p=0.048$) (Figure 6). Occupationally exposed former smokers ($n=17$) were also older with mean age at onset of 55.82 years ($SD\pm 10.75$) than the exposed non-smokers ($n=19$) who had a mean age at onset of 50.79 years ($SD\pm 9.50$) but this difference was not statistically significant ($p=0.145$) (Figure 7). A similar effect was found among unexposed nonsmokers ($n=13$) who were also younger than unexposed former smokers ($n=9$) but again this difference did reach statistical significance ($p=0.082$) (Figure 8). We also found that the percentage of



former smokers in the low exposure group was 61% (11/18) which was nearly double the percentage of former smokers in the high exposure group 33% (6/18) suggesting that some of the variance in age at onset of PD among subjects in the high and low exposure groups may have been due to smoking history.

Because the majority of subjects in this study were men we elected to determined if gender had any influence on age at onset PD. The sample population ($n=58$) included 13 women and 45 men. The mean age at onset of PD among the male subjects ($n=45$) was 55.49 years





(SD±11.03 years). The mean age at onset of PD among the female subjects (n=13) was 57.46 years (SD±10.98 years). Independent samples *t*-test indicated that gender did not significantly ($p=0.572$) influence age at onset among the subjects in this sample population (Figure 9).

Eleven of the subjects included in this study reported experiencing a loss of consciousness prior to the onset of their symptoms of PD. The age at onset among those subjects with a positive history for loss of consciousness was 59 years (SD±13.53). By contrast, the mean age at onset among the 45 subjects with a negative history for loss of consciousness was 55.2 years (SD±10.30). These findings indicate that loss of consciousness did not account for the younger age at onset found among the subjects with sporadic PD included in this study.

Discussion

Exposure history

The results of this study suggest that occupational exposure to metals and/or pesticides is associated with a significantly younger age at onset of idiopathic PD among subjects with no family history of the disease among their first-degree relatives. This observation is particularly important because in contrast to previous studies the data presented here indicate that the effect of occupational exposure to chemicals on age at onset of PD is significant even when the influence of heritable genetic factors is minimized by excluding subjects with a positive family history of the disease (Pezzoli *et al.*, 2000; Racette *et al.*, 2001).



To ascertain the effect of duration of exposure on age at onset of sporadic PD we stratified our subjects by duration of occupational exposure. Subjects in the high exposure group, which consisted of those subjects with longest duration of occupational exposure, were found to be significantly younger than the unexposed controls ($p=0.0121$). Although the subjects in the low exposure group were slightly younger than the unexposed controls, this difference was not statistically significant ($p=0.207$). Duration of occupational exposure to metals and/or pesticides negatively correlated with age at onset of PD in this study. However, the coefficient of determination indicated that only 15% of the variance in age at onset of PD was associated with exposure duration in this study. This observation indicates that other factors such as intensity or type of exposure and genetic factors that influence detoxification of neurotoxins may also play an important role in age at onset in exposed subjects with sporadic PD. It is important to note that herbicide exposure has been shown to modify the relationship between glutathione-S-transferase pi gene polymorphisms and age at onset in familial PD (Wilk *et al.*, 2006).

Estimating the level of exposure over a lifetime is difficult using historical exposure data obtained via questionnaire because this method does not provide for access to the actual occupational exposure levels necessary to ascertain the influence of exposure intensity on the outcome measured (Fidler *et al.*, 1987). The use of duration of exposure, which inherently ignores intensity of exposure, has its limitations but this parameter has nevertheless been used in many other studies (Hane *et al.*, 1977; Harkonen *et al.*, 1978; Lindstrom & Martelin, 1980; Seppalainen *et al.*, 1980; Iregren, 1982; Olson, 1982). These limitations of duration as the sole parameter are most likely reflected in our data, which suggest that 85% of the variance in age at onset PD seen in this study can be attributed to variables other than duration of exposure. These findings indicate the need for additional research using subjects with well-documented exposure history that will permit stratification by intensity as well as duration of exposure.

Analysis of the influence of exposure type on age at onset of PD in this study was conducted by stratifying our subjects into two groups based on whether they had been exposed primarily to metals or pesticides. Subjects who reported occupational exposure to metals were significantly younger than unexposed controls ($p=0.045$). Subjects exposed to pesticides were also younger than controls and that although this difference did not reach statistical significance ($p=0.057$) – there was a very strong trend. Comparison of mean age at onset of PD among subjects exposed to metals with that of subjects exposed to pesticides also failed to reveal a significant difference ($p=0.845$).

Previous reports suggest that subjects exposed to manganese (mean: 46 years) have a younger mean age at onset than subjects exposed to hydrocarbons (mean: 55.2 years). However, comparing the data sets from these two studies in an attempt to arrive at any conclusions about the effects of a specific chemical on age at onset of PD

is difficult since the exposure levels as well the specific type of chemical exposure may have varied considerably (Pezzoli *et al.*, 2000; Racette *et al.*, 2001). Although our findings also suggest that metal exposure may have a greater influence on age at onset than pesticide exposure additional research is nevertheless needed to ascertain how exposure to specific chemicals may differentially influence age at onset of sporadic PD.

Other factors possibly influencing age at onset of PD

Gender

Although men outnumbered women in this study, gender did not significantly influence age at onset of sporadic PD among subjects occupationally exposed to metals and/or pesticides. These data in subjects with sporadic PD are also consistent with the findings of Maher *et al.* (2002) who reported no difference in mean age at onset of PD among male and female siblings with PD. However, it should be noted that Maher *et al.* (2002) did find that females were more likely to have a first-degree relative with PD, suggesting that male subjects are more likely to be afflicted with sporadic PD. Since our subjects were derived from the same population this pattern may account for the ratio of males to females in our entire sample population of subjects with sporadic PD. The ratio of exposed males to females seen in this study is also consistent with other studies, which too have reported that men are more likely to have a history of occupational exposure to hydrocarbons and manganese than women (Pezzoli *et al.*, 2000; Racette *et al.*, 2001). More work is needed to determine how gender interacts with exposure history and genetics to influence age at onset of PD among subjects with sporadic and familial PD.

Smoking behavior

The results of this study revealed a significantly ($p=0.048$) older age at onset of PD among former smokers suggesting that smoking may provide a protective effect against the preclinical progression of sporadic PD. The effect of smoking on age at onset PD was opposite that of occupational exposure to metals and pesticides. Although smoking history was associated with an older age at onset, it most likely did not account for the older age at onset seen among the unexposed subjects in this study because smoking history was similar for the unexposed and exposed subjects. In fact, exposed subjects were actually more likely to have smoked than were unexposed subjects (47% versus 40% respectively) and therefore more likely to have been afforded the protective benefits of smoking.

The reduced risk for PD among smokers is fairly well documented but the effect of smoking on age at onset of sporadic PD is less clear (Smargiassi *et al.*, 1998; Taylor *et al.*, 1999; Hernan *et al.*, 2001; Petrovich *et al.*, 2002; Maher *et al.*, 2002). No association between age at onset and smoking history (smoked versus never smoked) has been observed in the GenePD study suggesting that the protective effect of smoking may be greater in sporadic PD than in familial PD (personal communication, Jemma Wilk).

Although inhibition of monoamine oxidase B (MAO B) is suspected to be involved in the reduced risk of PD, the mechanism by which smoking could slow the progression of PD has not been fully elucidated. MAO B polymorphisms such as the G to A transition in intron 13 have been shown to interact with catechol-O-methyltransferase (COMT) polymorphisms to influence relative risk for PD (Wu *et al.*, 2001). However, the MAO B intron 13 polymorphism does not appear to have a major role in the risk for PD, either by itself or by interacting with smoking (Hernan *et al.*, 2002). Additional research is needed to further elucidate on the role of these observations in age at onset of sporadic PD.

Prior head trauma and loss of consciousness

History of loss of consciousness prior to onset of PD was reported among eleven of the subjects included in this study. The age at onset among subjects in this study with a positive history for loss of consciousness was 59 years. By contrast, the mean age at onset among the 45 subjects in this study who reported a negative history for loss of consciousness was 55.2 years indicating that loss of consciousness could not possibly have accounted for the younger age at onset of PD we observed among the occupationally exposed subjects in this study.

The relationship between prior head trauma and/or loss of consciousness and risk for developing PD is unclear. A study by Factor and Weinstein (1991) evaluated the relationship between head trauma, loss of consciousness, and PD among 97 patients with PD. Sixty-four spouses served as controls. Thirty-one PD patients reported head trauma before onset of PD whereas only 11 controls reported head injury before completing the study survey. Twenty PD patients and five controls reported head injury associated with alteration or loss of consciousness. Injury occurred a mean of 37.7 years before onset of PD and 37.2 years before survey completion in the two groups, respectively. No significant differences were found between the two groups after controlling for sex. However, a trend toward significance was observed when examining head trauma with alteration of consciousness.

Other studies have found an association between a younger age at onset of PD among subjects who reported a history of head trauma and/or loss of consciousness prior to disease onset (Taylor *et al.*, 1999). Maher *et al.* (2002) found an association between head trauma and a younger age at onset of PD among a sample of 203 siblings pairs diagnosed with PD suggesting that factors such as head trauma which may contribute to a global loss of neurons throughout the central nervous system (CNS) as well as neuronal loss in the basal ganglia and substantia nigra may influence age at onset of PD.

Studies looking at young onset (<40 years old) PD patients found that head injury and exercise were the significant predictors of risk. Keeping all other variables constant, head injury was a risk factor and exercise appeared to be a protective factor. These findings suggest that head trauma may trigger and expedite the appearance of parkinsonian features, but such acceleration may

be prevented through regular exercise (Tsai *et al.*, 2002). More research is needed to determine how occupational exposures to neurotoxic chemicals and prior head trauma or loss of consciousness may interact to influence age at onset of sporadic PD.

Genetics

This research has expanded on the earlier work of Pezzoli *et al.* (2000) and Racette *et al.* (2001). Although Pezzoli *et al.* (2000) and Racette *et al.* (2001) provided evidence that age at onset of PD is influenced by occupational exposure to chemicals both studies failed to specifically control for known heritable genetic risk factors that may influence age at onset of PD by excluding subjects with a family history of the disease.

The influence of genetic factors on age at onset of PD were minimized in this study access the influence of metals and pesticides on age at onset of PD by excluding subjects with a positive family history of the disease among their first-degree relatives. Because genetic factors can influence age at onset of PD as well as lifetime risk for the disease, family history of PD must be considered when interpreting data related to age at onset of the disease. The greater similarity for age at onset than for year at onset among siblings with PD together with an increased risk for the disease among subject's biological relatives compared with subject's spouses stresses the importance of controlling for heritable genetic components (Maher *et al.*, 2002). Although we could not control for all genetic variables in this retrospective study, the results presented here nevertheless suggest that age at onset of PD is influenced by occupational exposure history in the absence of recognized heritable genetic risk factors for the disease.

The genetic factors that were able to control for in this study were those associated with a positive family history of the disease including: the ubiquitin C-terminal hydrolase gene located on chromosome 4p14/PARK5; the α -synuclein gene on chromosome 4q21-23/PARK1; and, the parkin gene located on chromosome 6q25-27/PARK2. α -Synuclein aggregation may be involved in Lewy body formation and in the pathogenesis of autosomal dominant forms of familial PD (Polymeropoulos *et al.*, 1997). The ubiquitin C-terminal hydrolase gene located on chromosome 4p14/PARK5 has been associated with autosomal dominant PD (Leroy *et al.*, 1998).

Unfortunately, even by excluding subjects with a positive family history of PD we could not fully control for the influence the parkin gene (Kitada *et al.*, 1998; Periquet *et al.*, 2003). Parkin mutations have been associated with about 15% of early-onset cases (≤ 45 years-old) without a family history of PD; this proportion decreased significantly with increasing age at onset (Periquet *et al.*, 2003). Because it is conceivable that some of the subjects with no family history in our sample population might still have the parkin gene mutation, future studies to control for this recessive genetic variable are recommended.

This study relied on retrospective data provided by the subjects about the medical history of their first-degree relatives. The lack of actual medical record reviews to confirm

the diagnoses should be recognized as a potential source of error. However, because this same method for subject selection has been used extensively in the GenePD study we therefore deemed it reliable for the purposes of this study as well (Maher *et al.*, 2002; DeStefano *et al.*, 2002).

Bias

Because the subjects evaluated in this study were selected first on the basis of familial history of PD selection bias was minimized and not based on exposure history per se selection bias was minimized. Occupational exposure history data was ascertained by a blinded interviewer who was not involved in the subject selection process nor in data analysis thereby further minimizing potential for selection bias. Stratification of subjects was performed by the PI but was based on exposure history alone with no regard for age at onset. All data on age at onset was ascertained after subjects were stratified by exposure history.

Conclusions

The results of this study suggest that environmental factors such as occupational exposure to metals and pesticides can influence age at onset of sporadic PD. This study is the first to demonstrate an association between occupational exposures to chemicals while attempting to specifically control for the influences of heritable genetic factors by excluding subjects with a positive family history of PD among first-degree relatives.

The results of this study also suggest that exposure duration is negatively correlated with age at onset of PD. However, because 85% of the variance in age onset of PD could be accounted for by other factors such as intensity of exposure, additional studies are needed to better define this relationship.

The observation that smoking is associated with an older age at onset among subjects with sporadic PD regardless of exposure history is intriguing. Additional research is needed to determine how smoking history differentially influences age at onset among subjects with sporadic and familial forms of PD.

The data from this study along with the previous findings of Racette *et al.* (2001) and Pezzoli *et al.* (2000) suggest that a common mechanism of action may underlie the effects of occupational chemical exposure on age at onset of PD. Because oxidative stress has been associated with PD and many of the chemicals these subjects were potentially exposed to may increase oxidative stress it is conceivable that increased oxidative stress is the common mechanism which may have hastened the progression of PD in these subjects. Future studies could be developed to test this hypothesis by ascertaining how genetic polymorphisms that influence the activity of enzymes such as glutathione-S-transferase which are involved in the metabolism and detoxification of neurotoxicants interact with exposure history to influence age at onset of sporadic PD (Offen *et al.*, 1996; Seaton *et al.*, 1997; Shimoda-Matsubayashi *et al.*, 1997; Menegon *et al.*, 1998; Feldman

& Ratner, 1999; Dawson & Dawson, 2003). Studies looking at age at onset of PD may help to provide information about the etiology as well as the progression of this disabling disease and may contribute to the development of novel preventative and therapeutic strategies.

Acknowledgements

This work is dedicated to the memory of Robert G. Feldman, M.D. for his unparalleled contributions to understanding, treating, and preventing Parkinson's disease. We would like to thank Genevieve Von Thesling for her assistance with subject intake. We would also like to thank Dr. Jemma Wilk for her assistance with the statistical analysis of the data for this project. This work was supported in part by a grant from the American Parkinson's Disease Association.

REFERENCES

- Ahmadi A, Fredrikson M, Jerregard H, Akerback A, Fall PA, Rannug A, Axelson O, Soderkvist P. (2000). GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. *Biochem Biophys Res Comm* **269**(3): 676–680.
- Andersen JK (2003) Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease. *Neurotoxicol Res* **5**(5): 307–313.
- Ascherio A, Chen H, Weisskopf MG, O'reilly E, McCullough ML, Calle EE, Schwarzschild MA, Thun MJ. (2006). Pesticide exposure and risk for Parkinson's disease. *Ann Neurol* **60**(2): 197–203
- Barbeau A, Roy M, Bernier G, Campanella G, Paris S. (1987). Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. *Can J Neurol Sci* **14**(1): 36–41.
- Beal MF. (2003). Mitochondria, oxidative damage, and inflammation in Parkinson's disease. *Ann NY Acad Sci* **991**: 120–131.
- Calne S, Schoenberg B, Martin W, Uitti RJ, Spencer P, Calne DB. (1987). Familial Parkinson's disease: possible role of environmental factors. *Can J Neurol Sci* **14**(3): 303–305.
- Dawson TM, Dawson VL. (2003). Molecular pathways of neurodegeneration in Parkinson's disease. *Science* **302**(5646): 819–822.
- DeStefano AL, Lew MF, Golbe LI, Mark MH, Lazzarini AM, Guttman M, Montgomery E, Waters CH, Singer C, Watts RL, Currie LJ, Wooten GF, Maher NE, Wilk JB, Sullivan KM, Slater KM, Saint-Hilaire MH, Feldman RG, Suchowersky O, Lafontaine AL, Labelle N, Growdon JH, Vieregge P, Pramstaller PP, Klein C, Hubble JP, Reider CR, Stacy M, MacDonald ME, Gusella JF, Myers RH. (2002). PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. *Am J Human Gen* **70**(5): 1089–1095.
- Di Llio C, Sacchetta P, Iannarelli V, and Aceto A. (1995). Binding of pesticides to alpha, mu and pi class glutathione transferase. *Toxicol Letters* **76**(2): 173–177.
- Dobson AW, Erikson KM, Aschner M. (2004). Manganese neurotoxicity. *Ann NY Acad Sci* **1012**: 115–128.
- Feldman RG, and Ratner MH. (1999). The pathogenesis of neurodegenerative disease: neurotoxic mechanisms of action and genetics. *Cur Opin Neurol* **12**(6): 725–731.
- Fidler AT, Baker EL, Letz RE. 1987. Estimation of long-term exposure to mixed solvents from questionnaire data: a tool for epidemiological investigations. *Brit J Ind Med* **44**(2): 133–141.
- Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R. (1996). Inhibition of monoamine oxidase B in the brains of smokers. *Nature* **379**(6567): 733–736.
- Ghione I, Di Fonzo A, Saladino F, Del Bo R, Bresolin N, Comi GP, Rango M. (2007). Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease. *Neurotoxicology*. **28**(3): 698–701.

- Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Kortsha GX, Brown GG, Richardson RJ. (1997). Occupational exposures to metals as risk factors for Parkinson's disease. *Neurology* **48**(3): 650–8.
- Gorell JM, Johnson CC, Rybicki BA, Peterson EL, Richardson RJ. 1998. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. *Neurology* **50**(5): 1346–1350.
- Gorell JM, Rybicki BA, Johnson CC, Peterson EL. (1999). Smoking and Parkinson's disease: a dose-response relationship. *Neurology* **52**: 115–119.
- Gu Z, Feng X, Dong X, Chan P. (2010). Smoking, genes encoding dopamine pathway and risk for Parkinson's disease. *Neurosci Lett*. **482**(1): 31–34.
- Gudelsky GA, Yamamoto BK. (2003). Neuropharmacology and neurotoxicity of 3,4-methylenedioxyamphetamine. *Methods Mol Med* **79**: 55–73.
- Hane M, Axelson O, Blume J, Hogstedt C, Sundell L, Ydreborg B. (1977). Psychological function changes among house painters. *Scand J Work Environ Health* **3**(2): 91–99.
- Hassoun E, Bagchi M, Bagchi D, Stohs SJ. (1993). Comparative studies on lipid peroxidation and DNA-single strand breaks induced by lindane, DDT, chlordane and endrin in rats. *Comp Biochem Physiol* **104**(3): 427–431.
- Hernan MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. (2001). Cigarette smoking and the incidence of Parkinson's disease in two prospective studies. *Ann Neurol* **50**(6): 780–786.
- Kamel F, Goldman SM, Umbach DM, Chen H, Richardson G, Barber MR, Meng C, Marras C, Korell M, Kasten M, Hoppin JA, Comyns K, Chade A, Blair A, Bhudhikanok GS, Webster Ross G, William Langston J, Sandler DP, Tanner CM. (2014) Dietary fat intake, pesticide use, and Parkinson's disease. *Parkinsonism Relat Disord*. **20**(1): 82–7.
- Khalil AA, Davies B, Castagnoli N Jr. (2006). Isolation and characterization of a monoamine oxidase B selective inhibitor from tobacco smoke. *Bioorg Med Chem*. **14**(10): 3392–3398.
- Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. *Nature* **392**(6676): 605–608.
- Klawans HL Jr, Cohen MM. (1970). Diseases of the extrapyramidal system. *Dis Mon Feb*: 1–52.
- Koller WC, Lyons KE, Truly W. (2004). Effect of levodopa treatment for parkinsonism in welders: A double-blind study. *Neurology* **62**(5): 730–733.
- Kuopio AM, Marttila RJ, Helenius H, Rinne UK. (1999). Changing epidemiology of Parkinson's disease in southwestern Finland. *Neurology* **52**(2): 302–308.
- Lee HJ, Shin SY, Choi C, Lee YH, Lee SJ. (2002). Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. *J Biol Chem* **277**(7): 5411–5417.
- Leroy E, Boyer R, Polymeropoulos MH. (1998). Intron-exon structure of ubiquitin c-terminal hydrolase-L1. *DNA Research* **5**(6): 397–400.
- Lindstrom K, Martelin T. (1980). Personality and long-term exposure to organic solvents. *Neurobehav Toxicol* **2**(2): 89–100.
- Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, Chen RC. (1997). Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. *Neurology* **48**(6): 1583–1588.
- Lücking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, Meco G, Deneffe P, Wood NW, Agid Y, Brice A. (2000). Association between early-onset Parkinson's disease and mutations in the parkin gene. *N Engl J Med* **342**(21): 1560–1567.
- Maher NE, Golbe LI, Lazzarini AM, Mark MH, Currie LJ, Wooten GF, Saint-Hilaire M, Wilk JB, Volcjak J, Maher JE, Feldman RG, Guttman M, Lew M, Waters CH, Schuman S, Suchowersky O, Lafontaine AL, Labelle N, Vieregge P, Pramstaller PP, Klein C, Hubble J, Reider C, Growdon J, Watts R, Montgomery E, Baker K, Singer C, Stacy M, Myers RH. (2002). Epidemiologic study of 203 sibling pairs with Parkinson's disease: the GenePD study. *Neurology* **58**(7): 79–84.
- McDonnell L, Maginnis C, Lewis S, Pickering N, Antoniak M, Hubbard R, Lawson I, Britton J. (2003). Occupational exposure to solvents and metals and Parkinson's disease. *Neurology* **61**(5): 716–717.
- Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG. (1998). Parkinson's disease, pesticides, and glutathione transferase polymorphisms. *Lancet* **352**(9137): 1344–1346. O'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, Ascherio A. (2005). Smokeless tobacco use and the risk of Parkinson's disease mortality. *Mov Disord*. **20**(10): 1383–1384.
- Peng J, Mao XO, Stevenson FF, Hsu M, Andersen JK. (2004). The herbicide paraquat induces dopaminergic nigral apoptosis through sustained activation of the JNK pathway. *J Biol Chem* **279**(31): 32626–32632.
- Periquet M, Lücking C, Vaughan J, Bonifati V, Durr A, De Michele G, et al. (2001). Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. *Am J Hum Genet* **68**(3): 617–626.
- Petrovitch H, Ross GW, Abbott RD, Sanderson WT, Sharp DS, Tanner CM, Masaki KH, Blanchette PL, Popper JS, Foley D, Launer L, White LR. (2002). Plantation work and risk of Parkinson disease in a population-based longitudinal study. *Arch Neurol* **59**(11): 1787–1792.
- Pezzoli G, Canesi M, Antonini A, Righini A, Perbellini L, Barichella M, Mariani CB, Tenconi F, Tesi S, Zecchinelli A, Leenders KL. (2000). Hydrocarbon exposure and Parkinson's disease. *Neurology* **55**(5): 667–673.
- Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. (1997). Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. *Science* **276**(5321): 2045–2047.
- Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S. (2000). A meta-analysis of Parkinson's disease and exposure to pesticides. *Neurotoxicology* **21**(4): 435–440.
- Racette BA, McGee-Minnich L, Moerlein SM, Mink JW, Videen TO, Perlmutter JS. (2001). Welding-related parkinsonism: clinical features, treatment, and pathophysiology. *Neurology* **56**(1): 8–13.
- Rajput AH, Uitti RJ, Stern W, Laverty W, O'Donnell K, O'Donnell D, Yuen WK, Dua A. (1987). Geography, drinking water chemistry, pesticides and herbicides and the etiology of Parkinson's disease. *Can J Neurol Sci* **14**: 414–418.
- Seidler A, Hellenbrand W, Robra BP, Vieregge P, Nischan P, Joerg J, Oertel WH, Ulm G, Schneider E. 1996. Possible environmental, occupational, and other etiologic factors for Parkinson's disease: a case-control study in Germany. *Neurology* **46**(5): 1275–1284.
- Seppalainen AM, Lindstrom K, Martelin T. (1980). Neurophysiological and psychological picture of solvent poisoning. *Am J Ind Med* **1**(1): 31–42.
- Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, Miller GW, Yagi T, Matsuno-Yagi A, Greenamyre JT. (2003). Mechanism of toxicity in rotenone models of Parkinson's disease. *J Neurosci* **23**(34): 10756–10764.
- Singh NK, Banerjee BD, Bala K, Basu M, Chhillar N. (2014) Gene-Gene and Gene-Environment Interaction on the Risk of Parkinson's Disease. *Curr Aging Sci*. [Epub ahead of print]
- Smargiassi A, Mutti A, De Rosa A, De Palma G, Negrotti A, Calzetti S. (1998). A case-control study of occupational and environmental risk factors for Parkinson's disease in the Emilia-Romagna region of Italy. *Neurotoxicology* **19**(4–5): 709–712.
- Smargiassi A, Mutti A. (1999). Peripheral biomarkers and exposure to manganese. *Neurotoxicology* **20**(2–3): 401–406.
- Sukata T, Uwagawa S, Ozaki K, Ogawa M, Nishikawa T, Iwai S, Kinoshita A, Wanibuchi H, Imaoka S, Funae Y, Okuno Y, Fukushima S. (2002). Detailed low-dose study of 1,1-bis(p-chlorophenyl)-2,2,2-trichloroethane carcinogenesis suggests the possibility of a hormetic effect. *Int J Cancer* **99**(1): 112–118.
- Tan EK, Tan C, Fook-Chong SM, Lum SY, Chai A, Chung H, Shen H, Zhao Y, Teoh ML, Yih Y, Pavanni R, Chandran VR, Wong MC. (2003). Dose-dependent protective effect of coffee, tea, and smoking in Parkinson's disease: a study in ethnic Chinese. *J Neurol Sci* **216**(1): 163–167.
- Tanner CM, Goldman SM. (1996) Epidemiology of Parkinson's disease. *Neurol Clin* **14**(2): 317–335.
- Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW. (2002). Smoking and Parkinson's disease in twins. *Neurology* **58**: 581–588.
- Tanner CM, Goldman SM, Ross GW, Grate SJ. (2014) The disease intersection of susceptibility and exposure: chemical exposures and neurodegenerative disease risk. *Alzheimers Dement*. **10**(3 Suppl): S213–25.
- Taylor CA, Saint-Hilaire MH, Cupples LA, Thomas CA, Burchard AE, Feldman RG, Myers RH. (1999). Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. *Am J Med Gen* **88**: 742–749.
- Thiruchelvam MJ, McCormack A, Richfield EK, Baggs RB, Tank AW, Di Monte DA, Cory-Slechta DA. (2003). Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. *Eur J Neurosci* **18**(3): 589–600.
- Thiruchelvam MJ, Powers JM, Cory-Slechta DA, Richfield EK. (2004). Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice. *Eur J Neurosci* **19**(4): 845–854.

- Twelves D, Perkins KS, Counsell C. (2003). Systematic review of incidence studies of Parkinson's disease. *Mov Disord* **18**(1): 19–31.
- Vermeulen RJ, Drukarch B, Sahadat MC, Goosen C, Wolters EC, Stoof JC. (1994). The dopamine D1 agonist SKF 81297 and the dopamine D2 agonist LY 171555 act synergistically to stimulate motor behavior of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian rhesus monkeys. *Mov Disord* **9**(6): 664–672.
- Ward CD, Gibb WR. (1990). Research diagnostic criteria for Parkinson's disease. *Adv Neurol* **53**: 245–249.
- Wilk JB, Tobin JE, Suchowersky O, Shill HA, Klein C, Wooten GF, et al. (2006) Herbicide exposure modifies GSTP1 haplotype association to Parkinson onset age: the Gene PD Study. *Neurology* **67**(12): 2206–2210.
- Wu MT, Pan CH, Huang YL, Tsai PJ, Chen CJ, Wu TN. (2003). Urinary excretion of 8-hydroxy-2-deoxyguanosine and 1-hydroxypyrene in coke-oven workers. *Environ Mol Mutagen* **42**(2): 98–105.